Q-omics provides the consensus-scored PUSL1 profile across patient tissues and cancer cell-line models. PUSL1 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PUSL1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, PUSL1 RNA expression shows 18,584 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where PUSL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PUSL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PUSL1 survival associations across molecular data types. PUSL1 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PUSL1 RNA expression–survival associations across cancer types. High PUSL1 expression shows unfavorable associations in KIRC, ACC, LIHC and LGG, but favorable associations in CHOL and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PUSL1 RNA expression.
This table summarizes PUSL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PUSL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PUSL1 shows higher tumor expression in COAD, KIRP, THCA, LIHC, LUAD and BLCA. The COAD box plot shows higher PUSL1 RNA expression in tumor versus normal tissue (log2 FC = +1.414, t-test p < 0.001).
This table shows molecular features associated with PUSL1 in patient tissues and cancer cell lines. In patient samples, PUSL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PUSL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
